Overview

Gender

male

Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century.
Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales.  Exit valuations were between $400M - $6B.  Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B.

Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome.  He has also been an investor, advisor, founder and CEO of several emerging market life science companies.

Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets.

Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms.

Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues.

Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King's College, London in collaboration with the LMB at Cambridge and Celltech.